Germacrone Inhibits Estrogen Receptor α-Mediated Transcription in MCF-7 Breast Cancer Cells

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Estrogen receptor (ER)α-positive breast cancer relies on ERα-mediated gene expression for growth.
• Inhibiting ERα signaling is a key strategy in breast cancer treatment.
• Germacrone, from Rhizoma curcuma, shows antitumor potential, but its mechanism is unknown.

Purpose of the Study:

• To elucidate the molecular mechanism of germacrone in inhibiting ERα-positive breast cancer cell proliferation.
• To investigate germacrone's effect on ERα-mediated gene expression at the transcriptional level.
• To evaluate germacrone's potential in combination therapy for breast cancer.

Main Methods:

• Utilized MCF-7 cells (ERα-positive breast cancer cell line).
• Assessed germacrone's impact on ERα recruitment to estrogen response elements (EREs).
• Examined the effect of germacrone on chromatin remodeling complex and RNA polymerase II binding.
• Evaluated germacrone's potentiation of methotrexate and 5-fluorouracil antitumor activity.

Main Results:

• Germacrone inhibits ERα-mediated gene expression transcriptionally in MCF-7 cells.
• Germacrone disrupts ERα binding to EREs, hindering chromatin accessibility.
• Germacrone compromises the assembly of SWI/SNF complex and RNA polymerase II at target promoters.
• Germacrone significantly enhances the antitumor effects of methotrexate and 5-fluorouracil.

Conclusions:

• Germacrone inhibits breast cancer cell proliferation by blocking ERα transcriptional activity.
• Germacrone's mechanism involves preventing ERα recruitment and subsequent transcription initiation.
• Germacrone shows promise as a therapeutic agent and in combination therapies for breast cancer treatment.